The Valley Desk

NCT02640209 · Interventional trial

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

Overall registry status Terminated

Early Phase 1

Conditions LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov